TY - JOUR
T1 - Device-related thrombus after left atrial appendage closure
T2 - Incidence, predictors, and outcomes
AU - Dukkipati, Srinivas R.
AU - Kar, Saibal
AU - Holmes, David R.
AU - Doshi, Shephal K.
AU - Swarup, Vijendra
AU - Gibson, Douglas N.
AU - Maini, Brijeshwar
AU - Gordon, Nicole T.
AU - Main, Michael L.
AU - Reddy, Vivek Y.
N1 - Funding Information:
Dr Kar reports Boston Scientific Corporation (significant): research grant support, advisory board, national principal investigator for CAP and CAP2, and proctor for left atrial appendage closure. Dr Doshi reports Boston Scientific Corporation (significant): research grant support, consultant, and national principal investigator for CAP2. Dr Swarup reports Boston Scientific Corporation (modest): research grant support and consultant; Johnson & Johnson (modest): research grant support and consultant; Abbott Inc (significant): research grant support and consultant; Sentreheart Inc (modest): research grant. Dr Gibson reports Boston Scientific Corporation (significant): consultant and proctor. Dr Maini reports Boston Scientific Corporation (significant): research grant support and advisory board; Medtronic (significant): research grant support and advisory board; Abbott Vascular (significant): research grant support and advisory board; Siemens (significant): research grant support and advisory board. Nicole Gordon reports Boston Scientific Corporation (significant): employee and stock. Dr Main reports Boston Scientific Corporation (significant): institutional research grant support and consultant. Dr Reddy reports Boston Scientific Corporation (significant): research grant support and consultant; Abbott Inc (significant): research grant support and consultant; Biosense-Webster Inc (significant): research grant support and consultant; Surecor Inc (significant): consultant and equity. Drs Dukkipati and Holmes have no disclosures to report.
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. METHODS: We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA2DS2-VASC and HAS-BLED scores. RESULTS: Of 1739 patients who received an implant (7159 patient-years follow-up; CHA2DS2-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18-5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90- 5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as follows: History of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26-4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19-4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08-3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01-1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94-0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. CONCLUSIONS: After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
AB - BACKGROUND: In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation. METHODS: We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578). Surveillance transesophageal echocardiographs were performed at 45 days and 12 months in all patients, and also at 6 months in the randomized control trials. We assessed both the incidence of DRT during these transesophageal echocardiographs (and other unscheduled transesophageal echocardiographs), and clinical outcomes of postprocedure stroke or systemic embolism (SSE) and adjusted for CHA2DS2-VASC and HAS-BLED scores. RESULTS: Of 1739 patients who received an implant (7159 patient-years follow-up; CHA2DS2-VASc=4.0), DRT was seen in 65 patients (3.74%). The rates of SSE with and without DRT were 7.46 and 1.78 per 100 patient-years (adjusted rate ratio, 3.55; 95% confidence interval [CI], 2.18-5.79; P<0.001), and ischemic SSE rates were 6.28 and 1.65 per 100 patient-years (adjusted rate ratio, 3.22; 95% CI, 1.90- 5.45, P<0.001). On multivariable modeling analysis, the predictors of DRT were as follows: History of transient ischemic attack or stroke (odds ratio [OR], 2.31; 95% CI, 1.26-4.25; P=0.007), permanent atrial fibrillation (OR, 2.24; 95% CI, 1.19-4.20; P=0.012); vascular disease (OR, 2.06; 95% CI, 1.08-3.91; P=0.028); left atrial appendage diameter (OR, 1.06 per mm increase; 95% CI, 1.01-1.12; P=0.019); left ventricular ejection fraction (OR, 0.96 per 1% increase; 95% CI, 0.94-0.99; P=0.009). DRT and SSE both occurred in 17 of 65 patients (26.2%). Of the 19 SSE events in these patients with DRT, 9 of 19 (47.4%) and 12 of 19 (63.2%) occurred within 1 and 6 months of DRT detection. Conversely, after left atrial appendage closure, most SSEs (123/142, 86.62%) occurred in patients without DRT. CONCLUSIONS: After left atrial appendage closure with Watchman, DRT (≈3.7%) is not frequent but, when present, is associated with a higher rate of stroke and systemic embolism.
KW - Atrial appendage
KW - Atrial fibrillation
KW - Percutaneous coronary intervention
KW - Stroke
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85052971898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052971898&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.118.035090
DO - 10.1161/CIRCULATIONAHA.118.035090
M3 - Article
C2 - 29752398
AN - SCOPUS:85052971898
SN - 0009-7322
VL - 138
SP - 874
EP - 885
JO - Circulation
JF - Circulation
IS - 9
ER -